09:11 AM EDT, 09/02/2025 (MT Newswires) -- Agilent Technologies ( A ) said Tuesday its MMR IHC Panel pharmDX has received class C companion diagnostic certification under EU in vitro diagnostic regulation for colorectal cancer.

The test, developed in collaboration with Bristol-Myers Squibb ( BMY ) , helps in identifying mismatch repair-deficient colorectal cancer patients eligible for treatment with Bristol-Myers Squibb's ( BMY ) Opdivo in combination with Yervoy, Agilent ( A ) said.